Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Comprehensive Cancer Centers of Nevada
Sponsor:
Collaborator:
Comprehensive Cancer Centers of Nevada
Information provided by (Responsible Party):
Wolfram Samlowski, Comprehensive Cancer Centers of Nevada
ClinicalTrials.gov Identifier:
NCT01565837
First received: March 26, 2012
Last updated: November 13, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2017
  Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)